Post‐COVID immunity in patients with solid tumor or hematological malignancies treated with SARS‐CoV‐2 monoclonal antibodies
All mAB-treated patients with malignancies developed polyfunctional immunity humoral and T-cell immunity to SARS-CoV-2 even in the setting of B-cell deficiency. The evolution of this immunity, including new variant-specific antibodies, without secondary illnesses suggests that patients were protected from symptomatic re-infection, and mAB therapy did not blunt the development of host immunity. Future studies are warranted to better characterize immunologic memory over time with exposures to new viral variants, evaluate prolonged viral shedding and the continued use of appropriate mAB for infection in high-risk patients.
Authors
- Jyotsna Fuloria
- John S. Schieffelin (ORCID: https://orcid.org/0000-0001-6642-5739)
- Bronwyn M. Gunn (ORCID: https://orcid.org/0000-0001-8904-9334)
- Gilberto Sabino‐Santos (ORCID: https://orcid.org/0000-0002-5462-5386)
- Sinem Ulusan (ORCID: https://orcid.org/0000-0002-1094-9792)
- Sruti Chandra
- Elizabeth B. Norton (ORCID: https://orcid.org/0000-0002-8426-3515)
- Lin Li (ORCID: https://orcid.org/0000-0003-1839-8048)
- Bo Ning (ORCID: https://orcid.org/0009-0002-3601-7544)
- Shuangyi Bai
- Ye Hu (ORCID: https://orcid.org/0000-0001-7255-5409)
- James E. Robinson (ORCID: https://orcid.org/0000-0002-9215-9523)
- Debra Elliott
- Cathryn Leggio
- Sam Litwin
- Ashley R. Smira
- Najia Waheed
- Anoli Karunathilake
Institutions
- Tulane University (US)
- University Medical Center New Orleans (US)
- Washington State University (US)
Publication Details
- Journal
- Immunity Inflammation and Disease
- Published
- 2024-12-01
- DOI
- https://doi.org/10.1002/iid3.70039
- Citations
- 2
- Primary Topic
- SARS-CoV-2 and COVID-19 Research
- Type
- article
- Field-Weighted Citation Impact
- 0.78
Funders
- Tulane University
- National Institutes of Health
- National Cancer Institute
- National Institute of Allergy and Infectious Diseases